Regulatory. SKYX continues to pursue mandatory regulation for the ceiling outlet receptacle, or weight support ceiling receptacle, as classified by the National Electric Code. SKYX has some heavyweights behind the push here, and we would not be surprised to see some type of resolution in the near term. Although mandatory classification could be a game-changer for the Company, the demonstrable savings in installation time, ease of swap-outs, and harm reduction benefits of SKYX’s system are sufficient to drive results, in our opinion.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
SSS. Improving Same Store Sales remains a key focus of management. In the first quarter of 2026, all brands saw sequential SSS growth, with STK reporting positive SSS and Benihana flat SSS. Even the Grill concepts have experienced a significant improvement in SSS over the past three quarters. ONE Group’s focus on providing value, the vibe experience, execution, and targeted marketing is paying dividends in a tough operating environment.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
The semiconductor sector just recorded one of its worst sessions of 2026. Broadcom fell approximately 15% Thursday after reporting fiscal second quarter results that beat earnings estimates but failed to raise full-year guidance — a distinction that matters enormously when a stock has run more than 90% year to date. The selloff spread immediately across the chip space. Micron dropped more than 6%, Marvell fell 5%, AMD declined 6%, and ARM Holdings lost nearly 9%. The Philadelphia Semiconductor Index, which had climbed 92% in 2026 heading into this week, shed more than 5% in a single session — one of its largest single-day drops since early 2025.
By Friday morning losses were extending. The two-day chip sector rout has now erased hundreds of billions in large cap market value in what has become one of the most closely watched sector corrections of the year.
What Actually Happened With Broadcom
The Broadcom report was not a fundamental collapse. Revenue for the quarter came in at $22.19 billion, up 48% year over year, with adjusted earnings per share of $2.44 beating the consensus estimate of $2.40. AI chip revenue grew more than 200% year over year. The company maintained its long-term target of semiconductor revenue exceeding $100 billion next fiscal year.
What rattled investors was a combination of two things. First, Q3 AI chip revenue guidance of approximately $16 billion came in below market expectations of $17.2 billion. Second, management reiterated rather than raised its 2026 full-year guidance — a significant signal to a market that had been pricing in continuous upward revisions. Separately, Broadcom is beginning to lose market share in supplying custom AI chips to Alphabet, with its share of Google’s tensor processing unit business expected to decline meaningfully through 2028 as a Taiwan-based competitor gains ground.
The underlying business did not break. Market expectations simply caught up with where the stock was trading. That is a valuation story, not a demand story — and that distinction matters considerably for how investors should interpret what happened.
Why This Matters for Smaller Semiconductor Companies
The selloff at the large cap level does not reflect a change in the fundamental demand environment driving chip sector growth. The five largest hyperscalers — Amazon, Alphabet, Meta, Microsoft, and Oracle — are collectively projecting $725 billion in capital expenditures in 2026, up 77% from the prior year’s already record-breaking level. Total AI infrastructure spending is projected at $7.6 trillion between 2026 and 2031. That capital does not flow exclusively through the top five chip companies. It moves through hundreds of suppliers, component manufacturers, and technology providers operating at every layer of the AI hardware stack.
Specialty materials companies, advanced packaging providers, power management chip designers, optical component manufacturers, and printed circuit board makers all sit in the downstream path of hyperscaler capital expenditure. Many of those companies operate well below the $2 billion market cap threshold and have not experienced the same run-up in valuations that left Broadcom, Micron, and AMD exposed to a guidance disappointment.
The pattern playing out this week is one the semiconductor sector has seen before. Extended rallies in large cap names draw increasing analyst scrutiny and tighter expectations — and when any element of those expectations goes unmet, the correction is sharp and immediate. Smaller companies in the same supply chain, carrying lower valuations and more modest expectations, tend to absorb that volatility differently.
For investors in smaller semiconductor names, Thursday’s large cap selloff is worth examining as a reference point rather than a warning signal. The AI infrastructure buildout that created the demand environment these companies operate in did not change on Thursday evening. The stock prices of a handful of mega cap chip companies did.
ATLANTA, June 04, 2026 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital transformation and cybersecurity, systems engineering and integration, and science research and development, today announced that it has filed a new shelf registration statement on Form S-3 with the United States Securities and Exchange Commission (“SEC”) to replace its expiring shelf registration statement. The registration statement was filed on June 4, 2026, and will become effective upon successful review by the SEC.
If and when it is declared effective, the registration statement will allow DLH to offer and sell, from time to time, up to $100 million of its equity securities; however, there are no current plans to do so. The Company has not issued any securities under the expiring registration statement. DLH filed the shelf registration statement to provide efficient access to equity markets if circumstances arise that would make the sale of securities advantageous to the Company.
These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. Following the effectiveness of the shelf registration statement, DLH may periodically offer one or more of the registered securities in amounts, at prices, and subject to terms to be announced when, and if, the securities are offered. The terms of any securities offered under the registration statement, and the intended use of the net proceeds resulting therefrom, will be established at the times of the offerings and will be described in prospectus supplements filed with the SEC at the times of the offerings.
This press release is not an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer of securities covered by the registration statement may be made solely by means of the prospectus included in the registration statement and a related prospectus supplement containing specific information about the terms of any such offering.
About DLH
DLH (NASDAQ: DLHC) enhances technology, public health, and cyber security readiness missions through science, technology, cyber, and engineering solutions and services. Our experts solve some of the most complex and critical missions faced by federal customers, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With a world-class workforce dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to innovative solutions to improve the lives of millions. For more information, visit www.DLHcorp.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH`s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward-looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding the anticipated use of proceeds. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements due to a variety of factors, including: the failure to achieve the anticipated benefits of any future acquisition (including anticipated future financial operating performance and results); the inability to retain employees and customers; contract awards in connection with re-competes for present business and/or competition for new business; our ability to manage our debt obligations; compliance with bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid and award protests, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; significant delays or reductions in appropriations for our programs and broader changes in U.S. government funding and spending patterns; legislation that amends or changes discretionary spending levels or budget priorities; legal, regulatory, and political changes from the federal government that could result in economic uncertainty; the impact of inflation and higher interest rates; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2025, as well as interim quarterly filings thereafter. The forward-looking statements contained herein are not historical facts, but rather based on current expectations, estimates, assumptions and projections about our industry and business.
Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements.
IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that updated results from an investigator-initiated trial being conducted at the University of Chicago Medicine Transplant Institute will be presented by Piotr Witkowski, M.D., Ph.D., Director of the Pancreas and Islet Transplant Program at UChicago Medicine, at the American Diabetes Association 86th Scientific Sessions, taking place June 5-9, 2026, in New Orleans, Louisiana.
Details of the oral presentation are as follows:
Presentation Title: Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation Session: Immune Modulatory Strategies for Next-Generation Cell Therapies Date: Sunday, June 7, 2026 Time: 2:30 p.m. – 3:00 p.m. CT Room: 343 (Level 3)
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact: Stephen Jasper Gilmartin Group (858) 525 2047 [email protected]
MAIA’s novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer
CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today provided a patient enrollment update for its ongoing pivotal Phase 3 trial, THIO-104, evaluating its novel telomere-targeting therapy as a third-line (3L) treatment for advanced non-small cell lung cancer (NSCLC). To date, 29 patients have been dosed among 34 activated trial sites in 6 foreign countries.
Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA, commented, “Enrollment and dosing in our Phase 3 study is progressing at a strong pace. Based on this early momentum, we are targeting up to 100 patients by year-end and expect to have sufficient survival data to conduct an interim analysis in 2027.”
Dr. Vitoc has previously stated that statistical assessments of MAIA’s lead therapeutic, ateganosine, suggest a high probability of technical success in the THIO-104 full approval trial if Phase 3 data is consistent with Phase 2 THIO-101 trial results. Median overall survival was 17.8 months in parts A and B of the Phase 2 trial. With chemotherapy, which is the standard utilized treatment for 3L NSCLC patients, expected survival in a heavily pre-treated population is 5.8 months.1
Ateganosine is a first-of-its-kind dual mechanism therapy designed to break down telomere structure and function in cancer cells while inducing immune activation. As a potential breakthrough therapeutic, ateganosine holds substantial commercial opportunity in a projected $70 billion global NSCLC treatment market by 2030.2
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine as a 3L NSCLC treatment.
About Ateganosine
Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About THIO-104 Phase 3 Clinical Trial
THIO-104 is a multicenter, open-label, randomized Phase 3 clinical trial, designed to evaluate ateganosine’s telomere-targeting anti-tumor activity when followed by PD-(L)1 inhibition in patients with advanced third-line NSCLC who previously did not respond or developed resistance to treatment regimens containing checkpoint inhibitor and/or chemotherapy and have progressed. The trial has two primary objectives: (1) to assess the clinical efficacy of ateganosine compared to investigator’s choice of chemotherapy, using median Overall Survival (OS) as the primary clinical endpoint (2) to evaluate the safety and tolerability of ateganosine in sequential combination with a checkpoint inhibitor. For more information on this Phase 3 trial, please visit ClinicalTrials.gov using the identifier NCT06908304.
About MAIA Biotechnology, Inc.
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Forward Looking Statements
MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.
1 Girard N, et al. J Thorac Onc 2009;12:1544-1549 2 Research and Markets, Non-Small Cell Lung Cancer (NSCLC) Global Market Trends and Regional Growth Insights 2026-2030, March 2026
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) — Xcel Brands (NASDAQ: XELB), a leading media and consumer products company specializing in building influencer-led brands through social commerce and livestream shopping, today announced the launch of OFF/DUTY by Coco Rocha, a new elevated fashion and accessories brand created in partnership with internationally renowned supermodel, entrepreneur, and fashion icon Coco Rocha. The collection will debut on QVC.
After more than two decades at the center of the fashion industry, Coco Rocha is bringing her unique perspective on style to consumers through a collection inspired by the pieces she has relied on throughout her career. From airports and backstage at fashion weeks to business meetings, school pickups, and international travel, OFF/DUTY by Coco Rocha is built around the belief that the most important pieces in a woman’s wardrobe are the ones she reaches for again and again. The collection combines effortless sophistication, versatility, and comfort with the confidence and polish that have become synonymous with Coco’s personal style.
Think of the oversized sweater thrown on between castings, the perfectly worn denim that transitions seamlessly from airport to dinner, the statement coat that instantly elevates a look, the chic tote that carries everything needed for a day navigating the streets of Paris, and the effortless layers, textures, and wardrobe staples that make getting dressed feel easy.
Known globally as the “Queen of Pose,” Coco Rocha has spent her career redefining the role of the modern supermodel. Having worked alongside the world’s leading fashion houses, celebrated designers, and renowned photographers while pioneering social media and personal branding within the industry, OFF/DUTY represents a natural evolution of her career, translating decades of industry expertise into a collection inspired by how women actually live and dress.
“Coco Rocha is one of the most recognizable and influential figures in fashion today. With OFF/DUTY by Coco Rocha, we are bringing Coco’s extraordinary fashion credibility, modern point of view, and global influence to QVC customers in an accessible and exciting way. The brand perfectly captures the intersection of luxury-inspired style and everyday versatility that today’s consumer is seeking,” said Robert D’Loren, Chairman and Chief Executive Officer of Xcel Brands.
“Fashion has always been about confidence and self-expression for me,” said Coco Rocha. “With OFF/DUTY by Coco Rocha, I wanted to create a collection that empowers women to feel elevated, stylish, and comfortable in every part of their lives, whether they’re traveling, working, relaxing, or stepping out. This brand reflects the pieces I genuinely love to wear when I’m off the runway and off duty.”
After spending more than twenty years wearing the creations of the world’s most celebrated designers, Coco Rocha is now sharing her own vision of modern dressing, one built not for the runway, but for the realities of everyday life.
About Xcel Brands
Xcel Brands, Inc. (NASDAQ: XELB) is a media and consumer products company engaged in the design, licensing, marketing, live streaming, and social commerce sales of branded apparel, footwear, accessories, fine jewelry, home goods, pet products and other consumer products, and the acquisition of dynamic consumer lifestyle brands. Xcel was founded in 2011 with a vision to reimagine shopping, entertainment, and social media as social commerce. Xcel is an industry leader in developing influencer led brands and owns the Halston and C. Wonder brands, as well as the co-branded influencer led brands Tower Hill by Christie Brinkley, Trust. Respect. Love by Cesar Millan, GemmaMade by Gemma Stafford and Off/Duty by Coco Rocha brand and holds noncontrolling interests or long-term license agreement in Mesa Mia by Jenny Martinez. Xcel also owns and manages the Longaberger by Shannon Doherty brand through its controlling interest in Longaberger Licensing, LLC. Xcel is pioneering a modern consumer products sales strategy which includes the promotion and sale of products under its brands through interactive television, digital live-stream shopping, social commerce, brick-and-mortar retailers, and e-commerce channels to be everywhere its customers’ shop. The company’s previously owned and current brands have generated more than $5 billion in retail sales via livestreaming in interactive television and digital channels alone and has over 20,000 hours of content production time in live-stream and social commerce. The brand portfolio reaches more than 46 million social media followers with broadcast reaching 200 million households. Headquartered in New York City, Xcel Brands is led by an executive team with significant live streaming, production, merchandising, design, marketing, retailing, and licensing experience, and a proven track record of success in elevating branded consumer products companies. For more information, visit www.xcelbrands.com.
Toronto, Ontario–(Newsfile Corp. – June 4, 2026) – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) (“Aurania” or the “Company”) announces that its Annual and Special Meeting of Shareholders (the “Meeting”) will be held at 1:30pm ET on Thursday, June 11, 2026, at the Company’s offices at 8 King Street East, Suite 1800, Toronatuanto, ON M5C 1B5.
Following the conclusion of the formal portion of the meeting, Aurania’s President & CEO, Dr. Keith Barron will provide an update on the Company’s projects. A video and/or audio replay of this update is expected to be made available after the meeting.
Proxy Voting Deadline
To ensure your vote is counted, please cast your vote prior to Tuesday, June 9th, 2026, at 1:30pm ET as per the details in your form of proxy.
Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and critical energy in Europe and abroad.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
The US labor market delivered its strongest headline surprise of 2026 on Friday morning. The Bureau of Labor Statistics reported the economy added 172,000 jobs in May, nearly doubling the 88,000 that economists surveyed by Bloomberg had anticipated. The unemployment rate held steady at 4.3%. The report landed alongside upward revisions to prior months: April’s original 115,000 payroll figure was revised to 179,000, and March was adjusted to 214,000, marking the first monthly gain above 200,000 since early 2024.
On the surface, the numbers paint a picture of a labor market that has defied repeated predictions of deterioration. Beneath the surface, the report is more complicated.
May’s gains were notably broad-based rather than concentrated in the healthcare sector, which has been the primary engine of US job growth for the better part of two years. Leisure and hospitality led all sectors with 70,000 new positions, followed by local government at 55,000 and healthcare at approximately 35,000. Food services and drinking places contributed 48,000 of the leisure and hospitality total.
That sectoral breakdown matters for context. A Bank of America Institute analysis released this week found that while May payroll growth accelerated, much of the underlying strength appears to be concentrated in lower-income job categories. Average hourly earnings for food services workers, one of the month’s largest contributing sectors, stand at $21.86 according to government data. Across the full economy, average hourly earnings grew 3.4% year over year in May, a pace that continues to track below the current rate of consumer price inflation.
The Federal Reserve’s Beige Book, released Wednesday, reinforced this picture at the ground level. Eleven of the Fed’s 12 districts described a low-hire, low-fire environment, with workers increasingly reluctant to change jobs amid broader economic uncertainty. The report noted that hiring across most districts remained selective and primarily focused on critical roles or attrition replacement rather than expansion.
For investors tracking monetary policy, Friday’s report arrives at a sensitive moment. Federal Reserve Chair Kevin Warsh presides over his first FOMC meeting June 16-17, and a labor market printing nearly double expectations gives the committee additional justification to hold rates steady. Markets had already priced in more than an 80% probability of a June hold heading into this week. A 172,000 payroll print is unlikely to change that calculus and may further push rate cut expectations into 2027.
The jobs report delivers a split verdict for the sub-$2 billion market cap space. The 70,000 jobs added in leisure and hospitality represent real incremental consumer activity that flows directly through to small cap restaurant operators, regional hospitality companies, and travel-adjacent businesses that have been managing through an uneven demand environment. More workers employed in discretionary spending sectors is a near-term tailwind for these names.
The counterweight is the Fed. A stronger-than-expected labor market that keeps the central bank on hold extends the timeline for the rate relief that smaller, variable-rate borrowers have been waiting on. Until wage growth catches up with inflation and gives the Fed room to ease, the rate environment for small cap balance sheets remains a structural headwind regardless of how many jobs the economy adds each month.
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Term Loan Repricing. V2X successfully repriced its approximately $869 million First Lien Term Loan. The repricing improves the applicable interest rate to SOFR plus an applicable margin of 2.0%, with an additional 25 basis-point reduction upon achieving specific corporate credit ratings of Ba3 (stable outlook) from Moody’s and BB (stable outlook) from S&P. The repricing also reduced the SOFR floor from 0.75% to 0.00%.
Implications. The transaction immediately lowers the Company’s borrowing costs and positions V2X to realize interest savings as the Company’s financial profile continues to strengthen. While the actual amount of interest savings will depend on SOFR rates, the transaction enhances the Company’s cost of capital and increases value for shareholders, in our view. With the closing, V2X has now successfully repriced its First Lien Term Loan four times since October 2023, highlighting the ongoing improvement in the Company’s financial profile, as well as the increased opportunity set, in our opinion.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Labor Market Sustained Momentum? U.S. private employers added 122,000 jobs in May, according to ADP, exceeding the 120,000 consensus estimate and up from April’s 105,000 revised number. ADP noted, “The labor market continues to show sustained momentum going into the summer hiring season.” While still early, these improving green shoots provide encouragement for the second half improvement in Kelly’s business, in our view.
Broad-Based. ADP noted the hiring was more broad-based in May than in the last few years, with eight of the ten supersectors ADP tracks posting positive momentum. Gains were led by the education and health care sectors.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
BOTHELL, Wash., June 03, 2026 (GLOBE NEWSWIRE) — Cocrystal Pharma Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing need for effective, safe antiviral treatments, has appointed James Sapirstein Chief Executive Officer, effective immediately. The Company also plans to appoint Mr. Sapirstein as a member of the Board of Directors. He has extensive pharmaceutical industry leadership and development experience. Mr. Sapirstein replaces Sam Lee and Jim Martin, who served as Co-Chief Executive Officers. Sam Lee will continue as President and transition to Chief Scientific Officer, and Jim Martin will continue as Chief Financial Officer.
“James brings the right experience in the biopharma business as we’re accelerating the advancement of multiple clinical programs,” said Roger Kornberg, Ph.D., Chairman of Cocrystal Pharma. “We have known him for many years, and our management team and board are appreciative of his decision to join us as Chief Executive Officer.”
Mr. Sapirstein commented, “Cocrystal’s pipeline comprises transformative antivirals developed using its structure based drug discovery platform. We are well positioned with the right technology and team to create meaningful benefits for patients as well as our shareholders. The potential to address the need for new antivirals is highly motivating for me with my product development and launch background.”
Mr. Sapirstein has participated in or led 23 product launches. He has also driven numerous business development transactions. Mr. Sapirstein was Chief Executive Officer of Contravir Pharmaceuticals, served as the founding Chief Executive Officer of Tobira Therapeutics, and as Executive Vice President, Metabolic and Endocrinology, for Serono Laboratories.
Earlier in his career, he held senior marketing and commercialization positions, at Gilead Sciences and director of international marketing of the infectious disease division at Bristol Myers Squibb.
Mr. Sapirstein is a member of several industry boards and previously served as Chairman of BioNJ as well as Biotechnology Innovation Organization board member for more than a decade. He is also a founding member of the board of advisors of the Miami Biotech Collective.
About Cocrystal Pharma’s Structure-Based Drug Discovery Platform
Cocrystal Pharma is leveraging its structure based drug discovery platform technology to design next generation antiviral candidates that precisely target viral replication mechanisms. By binding to highly conserved regions of viral enzymes, the Company’s compounds aim to maintain potency against mutating strains while minimizing off target effects, offering potentially safer, broad spectrum antiviral solutions. This approach streamlines candidate identification and optimization, enabling more rapid progression of promising therapies with robust resistance and safety profiles.
The Company’s platform provides a three dimensional structure of inhibitor complexes at near-atomic resolution, providing immediate insight to guide Structure Activity Relationships. This helps identify novel binding sites and enables a rapid turnaround of structural information through highly automated X-ray data processing and refinement. This technology permits the development of novel broad spectrum antivirals.
About Cocrystal Pharma
Cocrystal Pharma Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and hepatitis C viruses. Cocrystal employs unique structure based technologies to create viable antiviral drugs. For more information, visit www.cocrystalpharma.com.
RESTON, Va., June 3, 2026 /PRNewswire/ — V2X, Inc. (NYSE: VVX), today announced the successful repricing of its approximately $869 million First Lien Term Loan. The repricing improves the applicable interest rate to SOFR plus an applicable margin of 2.0%, with an additional 25 basis-point-reduction upon achieving specific corporate credit ratings of Ba3 (stable outlook) from Moody’s and BB (stable outlook) from S&P. The repricing also reduced the SOFR floor from 0.75% to 0.00%.
“This transaction immediately lowers our borrowing costs and positions us to realize interest savings as our financial profile continues to strengthen,” said Shawn Mural, Senior Vice President and Chief Financial Officer of V2X. “The repricing provides a 25-basis-point reduction in our applicable margin, with the opportunity for an additional 25-basis-point reduction upon achieving and maintaining specified credit ratings. These savings are expected to drive lower interest expense, enhance our cost of capital, and increase value for shareholders.”
With the closing on Friday May 29, 2026, V2X has now successfully repriced its First Lien Term Loan four times since October 2023.
About V2X V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.
Investor Contact Mike Smith, CFA Vice President, Treasury, Corporate Development and Investor Relations [email protected] 719-637-5773
